MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626002280?dgcid=rss_sd_all
MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626002280?dgcid=rss_sd_all
“MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study.” The Lancet Haematology.
@article{article68457,
title = {MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626002280?dgcid=rss_sd_all}
}